How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/myocardial-infarction-prevention.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Myocardial Infarction Prevention — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Myocardial Infarction Prevention (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Myocardial Infarction Prevention, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Zontivity	VORAPAXAR	Key Therap	Protease-activated Receptor-1 Antagonist	Proteinase-activated receptor 1	2014-01-01
Crestor	rosuvastatin	AstraZeneca	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	2003-01-01
Micardis	TELMISARTAN	Boehringer Ingelheim	Angiotensin 2 Receptor Blocker [EPC]	Type-2 angiotensin II receptor	1998-01-01
Lipitor	atorvastatin	Pfizer Inc.	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	1996-12-17
Lipitor	Atorvastatin Calcium	Pfizer	atorvastatin	3-hydroxy-3-methylglutaryl-coenzyme A reductase	1996-01-01
Aceon	PERINDOPRIL ARGININE	Symplmed Pharms Llc	Angiotensin Converting Enzyme Inhibitor	Angiotensin-converting enzyme	1993-01-01
Norvasc	amlodipine	Pfizer Inc.	Calcium channel blocker (dihydropyridine)	Aldehyde oxidase, Voltage-dependent calcium channel gamma-1 subunit, 5-hydroxytryptamine receptor 6	1992-07-31
Altace	RAMIPRIL	King Pfizer	Angiotensin Converting Enzyme Inhibitor [EPC]	Angiotensin-converting enzyme	1991-01-01
Mevacor	LOVASTATIN	Merck & Co.	HMG-CoA Reductase Inhibitor	3-hydroxy-3-methylglutaryl-coenzyme A reductase	1987-01-01
Zocor	simvastatin	Merck & Co.	HMG-CoA Reductase Inhibitor [EPC]	Nuclear receptor subfamily 1 group I member 3, Nuclear receptor subfamily 4 group A member 2, 3-hydroxy-3-methylglutaryl-coenzyme A reductase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Boehringer Ingelheim · 2 drugs in Myocardial Infarction Prevention
Pfizer Inc. · 2 drugs in Myocardial Infarction Prevention
Merck & Co. · 2 drugs in Myocardial Infarction Prevention
King Pfizer · 1 drug in Myocardial Infarction Prevention
Pfizer · 1 drug in Myocardial Infarction Prevention
AstraZeneca · 1 drug in Myocardial Infarction Prevention
Symplmed Pharms Llc · 1 drug in Myocardial Infarction Prevention
DongKoo Bio & Pharma · 1 drug in Myocardial Infarction Prevention
Key Therap · 1 drug in Myocardial Infarction Prevention

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Myocardial Infarction Prevention:

Cite this brief

Drug Landscape (2026). Myocardial Infarction Prevention — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/myocardial-infarction-prevention. Accessed 2026-06-10.

Myocardial Infarction Prevention full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing